KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Ken Kato; Manish A. Shah; Peter Enzinger; Jaafar Bennouna; Lin Shen; Antoine Adenis; Jong Mu Sun; Byoung Chul Cho; Mustafa Özgüroǧlu; Takashi Kojima; Vladimir Kostorov; Cinta Hierro; Ying Zhu; Lee Anne McLean; Sukrut Shah; Toshihiko Doi

doi:10.2217/fon-2018-0609

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Ken Kato
, Manish A. Shah
, Peter Enzinger
, Jaafar Bennouna
, Lin Shen
, Antoine Adenis
, Jong Mu Sun
, Byoung Chul Cho
, Mustafa Özgüroǧlu
, Takashi Kojima
, Vladimir Kostorov
, Cinta Hierro
, Ying Zhu
, Lee Anne McLean
, Sukrut Shah
, Toshihiko Doi

Research output: Contribution to journal › Article › peer-review

155 Scopus citations

Abstract

Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. Aim: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov: NCT03189719.

Original language	English
Pages (from-to)	1057-1066
Number of pages	10
Journal	Future Oncology
Volume	15
Issue number	10
DOIs	https://doi.org/10.2217/fon-2018-0609
State	Published - Apr 2019
Externally published	Yes

Keywords

chemotherapy
esophageal cancer
esophagogastric junction cancer
gastrointestinal/esophageal
immunotherapy
PD-1
PD-L1
pembrolizumab
squamous cell carcinoma of the esophagus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2018-0609

Cite this

Kato, K., Shah, M. A., Enzinger, P., Bennouna, J., Shen, L., Adenis, A., Sun, J. M., Cho, B. C., Özgüroǧlu, M., Kojima, T., Kostorov, V., Hierro, C., Zhu, Y., McLean, L. A., Shah, S., & Doi, T. (2019). KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncology, 15(10), 1057-1066. https://doi.org/10.2217/fon-2018-0609

@article{8a9f017c188e487a9aed52b96c1daea5,

title = "KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer",

abstract = "Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. Aim: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry \& ID: ClinicalTrials.gov: NCT03189719.",

keywords = "chemotherapy, esophageal cancer, esophagogastric junction cancer, gastrointestinal/esophageal, immunotherapy, PD-1, PD-L1, pembrolizumab, squamous cell carcinoma of the esophagus",

author = "Ken Kato and Shah, \{Manish A.\} and Peter Enzinger and Jaafar Bennouna and Lin Shen and Antoine Adenis and Sun, \{Jong Mu\} and Cho, \{Byoung Chul\} and Mustafa {\"O}zg{\"u}roǧlu and Takashi Kojima and Vladimir Kostorov and Cinta Hierro and Ying Zhu and McLean, \{Lee Anne\} and Sukrut Shah and Toshihiko Doi",

note = "Publisher Copyright: {\textcopyright} 2019 2019 Future Medicine Ltd.",

year = "2019",

month = apr,

doi = "10.2217/fon-2018-0609",

language = "English",

volume = "15",

pages = "1057--1066",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "10",

}

Kato, K, Shah, MA, Enzinger, P, Bennouna, J, Shen, L, Adenis, A, Sun, JM, Cho, BC, Özgüroǧlu, M, Kojima, T, Kostorov, V, Hierro, C, Zhu, Y, McLean, LA, Shah, S & Doi, T 2019, 'KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer', Future Oncology, vol. 15, no. 10, pp. 1057-1066. https://doi.org/10.2217/fon-2018-0609

TY - JOUR

T1 - KEYNOTE-590

T2 - Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

AU - Kato, Ken

AU - Shah, Manish A.

AU - Enzinger, Peter

AU - Bennouna, Jaafar

AU - Shen, Lin

AU - Adenis, Antoine

AU - Sun, Jong Mu

AU - Cho, Byoung Chul

AU - Özgüroǧlu, Mustafa

AU - Kojima, Takashi

AU - Kostorov, Vladimir

AU - Hierro, Cinta

AU - Zhu, Ying

AU - McLean, Lee Anne

AU - Shah, Sukrut

AU - Doi, Toshihiko

PY - 2019/4

Y1 - 2019/4

N2 - Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. Aim: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov: NCT03189719.

AB - Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. Aim: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov: NCT03189719.

KW - chemotherapy

KW - esophageal cancer

KW - esophagogastric junction cancer

KW - gastrointestinal/esophageal

KW - immunotherapy

KW - PD-1

KW - PD-L1

KW - pembrolizumab

KW - squamous cell carcinoma of the esophagus

UR - https://www.scopus.com/pages/publications/85064212073

U2 - 10.2217/fon-2018-0609

DO - 10.2217/fon-2018-0609

M3 - Article

C2 - 30735435

AN - SCOPUS:85064212073

SN - 1479-6694

VL - 15

SP - 1057

EP - 1066

JO - Future Oncology

JF - Future Oncology

IS - 10

ER -

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this